President/CMO Michael Goldstein to depart June 30; Rabia Ozden named new CMO

OCULAR THERAPEUTIX, INC

Michael Goldstein, President Ophthalmology and CMO, leaves OCUL on June 30, 2022.
Rabia Gurses Ozden, SVP Clinical Development, becomes Chief Medical Officer on July 1, 2022.
Goldstein enters consulting agreement from July 2022 to June 2023, renewable to 2026, at $6,000/month.
Consulting agreement includes non-competition and non-solicitation provisions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Goldstein

President, Ophthalmology and Chief Medical Officer

OCUL · OCULAR THERAPEUTIX, INC

Effective: 2022-06-30
Successor: Rabia Gurses Ozden
Filed: June 8, 2022, 7:59 PM ET

On June 3, 2022, Michael Goldstein, M.D., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, Inc. (the “Company”) and the Company mutually agreed that Dr. Goldstein would depart the Company to pursue other business opportunities, effective June 30, 2022 (the “Separation Date”).

Appointed

Rabia Gurses Ozden

Chief Medical Officer

OCUL · OCULAR THERAPEUTIX, INC

Effective: 2022-07-01
Filed: June 8, 2022, 7:59 PM ET

In connection with his departure, Rabia Gurses Ozden, M.D., Senior Vice President, Clinical Development of the Company, has agreed to assume the role of Chief Medical Officer of the Company, effective on July 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Goldstein departed as President, Ophthalmology and Chief Medical Officer at OCULAR THERAPEUTIX, INC.

Action: departed
Role: President, Ophthalmology and Chief Medical Officer

Exact text from the filing

On June 3, 2022, Michael Goldstein, M.D., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, Inc. (the “Company”) and the Company mutually agreed that Dr. Goldstein would depart the Company to pursue other business opportunities, effective June 30, 2022 (the “Separation Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Rabia Gurses Ozden was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

In connection with his departure, Rabia Gurses Ozden, M.D., Senior Vice President, Clinical Development of the Company, has agreed to assume the role of Chief Medical Officer of the Company, effective on July 1, 2022.

View on SEC.gov

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-22-069168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.